Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee

Volltext

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer von Long, G.V., Tykodi, S.S., Schneider, J.G., Garbe, C., Gravis, G., Rashford, M., Agrawal, S., Grigoryeva, E., Bello, A., Roy, A., Rollin, L., Zhao, X.

Volltext

Editorial: Immune checkpoint inhibitors in renal cell carcinoma von Tykodi, Scott S, Pichler, Renate

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer von Brahmer, Julie R, Tykodi, Scott S, Chow, Laura Q.M, Hwu, Wen-Jen, Topalian, Suzanne L, Hwu, Patrick, Drake, Charles G, Camacho, Luis H, Kauh, John, Odunsi, Kunle, Pitot, Henry C, Hamid, Omid, Bhatia, Shailender, Martins, Renato, Eaton, Keith, Chen, Shuming, Salay, Theresa M, Alaparthy, Suresh, Grosso, Joseph F, Korman, Alan J, Parker, Susan M, Agrawal, Shruti, Goldberg, Stacie M, Pardoll, Drew M, Gupta, Ashok, Wigginton, Jon M

Volltext

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma von Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander, Cho, Daniel C., Guan, Shanhong, Puente, Erika, Tuan Nguyen, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.

Volltext

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random... von Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M

Volltext

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors von Torikai, Hiroki, Reik, Andreas, Soldner, Frank, Warren, Edus H., Yuen, Carrie, Zhou, Yuanyue, Crossland, Denise L., Huls, Helen, Littman, Nicholas, Zhang, Ziying, Tykodi, Scott S., Kebriaei, Partow, Lee, Dean A., Miller, Jeffrey C., Rebar, Edward J., Holmes, Michael C., Jaenisch, Rudolf, Champlin, Richard E., Gregory, Philip D., Cooper, Laurence J.N.

Volltext

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system von Miller, Chris P, Fung, Megan, Jaeger-Ruckstuhl, Carla A, Xu, Yuexin, Warren, Edus H, Akilesh, Shreeram, Tykodi, Scott S

Volltext

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial von Tykodi, Scott S, Gordan, Lucio N, Alter, Robert S, Arrowsmith, Edward, Harrison, Michael R, Percent, Ivor, Singal, Rakesh, Van Veldhuizen, Peter, George, Daniel J, Hutson, Thomas, Zhang, Joshua, Zoco, Jesus, Johansen, Jennifer L, Rezazadeh Kalebasty, Arash

Volltext

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition von Buchbinder, Elizabeth I, Dutcher, Janice P, Daniels, Gregory A, Curti, Brendan D, Patel, Sapna P, Holtan, Shernan G, Miletello, Gerald P, Fishman, Mayer N, Gonzalez, Rene, Clark, Joseph I, Richart, John M, Lao, Christopher D, Tykodi, Scott S, Silk, Ann W, McDermott, David F

Volltext

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence von Tykodi, Scott S

Volltext

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma von Rini, Brian I, Signoretti, Sabina, Choueiri, Toni K, McDermott, David F, Motzer, Robert J, George, Saby, Powles, Thomas, Donskov, Frede, Tykodi, Scott S, Pal, Sumanta K, Gupta, Saurabh, Lee, Chung-Wei, Jiang, Ruiyun, Tannir, Nizar M

Volltext

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma von Xu, Yuexin, Miller, Chris P., Warren, Edus H., Tykodi, Scott S.

Volltext

Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor von Tretiakova, Maria S., Kehr, Elizabeth L., Gore, John L., Tykodi, Scott S.

Volltext

Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study von Sillah, Arthur, Peters, Ulrike, Watson, Nathaniel F., Tykodi, Scott S., Hall, Evan T., Silverman, Allison, Malen, Rachel C., Thompson, John A., Lee, Sylvia M., Bhatia, Shailender, Veatch, Joshua, Warner, Jeannie, Thornton, Timothy, Phipps, Amanda I.

Volltext

Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors von Xu, Yuexin, Miller, Chris P, Tykodi, Scott S, Akilesh, Shreeram, Warren, Edus H

Volltext

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma von Yang, Yuanquan, Psutka, Sarah P., Parikh, Anish B., Li, Mingjia, Collier, Katharine, Miah, Abdul, Mori, Sherry V., Hinkley, Megan, Tykodi, Scott S., Hall, Evan, Thompson, John A., Yin, Ming

Volltext

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era von Macleod, Liam C, Tykodi, Scott S, Holt, Sarah K, Wright, Jonathan L, Lin, Daniel W, Tretiakova, Maria S, True, Lawrence D, Gore, John L

Volltext

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded cl... von Xu, Yuexin, Morales, Alicia J., Towlerton, Andrea M. H., Akilesh, Shreeram, Miller, Chris P., Tykodi, Scott S., Warren, Edus H.

Volltext